DIL Dyadic International

Dyadic International, Inc. (AMEX:DIL), a biotechnology company engaged in the development, manufacture and sale of biological products, announced today that its President and CEO, Mark Emalfarb, will present at The Wall Street Analyst Forum, to be held on February 27th - March 2nd, 2006 at The Princeton Club on 15 West 43rd St. in New York. The presentation will take place at 9:40 a.m. EST on Wednesday, March 1, 2006, and will be webcast live. An archive of the webcast will be available for 30 days. To access the live webcast or archived presentation, please go to http://www.dyadic-group.com. About Dyadic Dyadic International, Inc., is engaged in the development, manufacture and sale of proteins, enzymes and other bio-molecules, as well as the licensing of its enabling proprietary technology to collaborators for the discovery, development and manufacture of biological products from genes. Dyadic markets its products and services for applications in the textile, chemical, agricultural, pulp & paper, pharmaceutical, biotechnology and other industries, using its proprietary C1 Host Technology and C1 Expression and Screening Systems for the discovery, development and production of biological products. Cautionary Statement for Forward-Looking Statements Certain statements contained in this press release are "forward-looking statements." These forward-looking statements involve risks and uncertainties that could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. For a discussion of these risks and uncertainties, please see our filings from time to time with the Securities and Exchange Commission, which are available free of charge on the SEC's web site at http://www.sec.gov, including our Annual Report on Form 10-KSB for the year ended December 31, 2004, and our Quarterly Report on Form 10-QSB for the quarter ended September 30, 2005. Except as required by law, we expressly disclaim any intent or obligation to update any forward-looking statements.